Russian govt to provide additional preferences to domestic full-cycle drugmakers

The Russian government plans to conduct a pilot project in the domestic pharmaceutical sector that will involve conducting state procurements of drugs manufactured by companies that have a full-cycle production in one of the countries of the Eurasian Economic Union (EAEU).

This, according to the state, will make localization in the EAEU more attractive for foreign pharmaceutical companies, reports The Pharma Letter’s local correspondent.

The experiment concerns drugs that fall into 15 international non-proprietary names. Seven of them are used to treat HIV infection, four are cancer, two are anti-diabetics, while the remaining two are for treatment of tuberculosis.